Global Drug Device Combination Products Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Drug Device Combination Products Market is presumed to reach the market size of nearly USD 296.74 Billion by 2032 from USD 144.66 Billion in 2023 with a CAGR of 8.31% under the study period 2024-2032.

Drug device combination products are medical products that combine a drug or biologic substance with a medical device to deliver therapeutic benefits or perform specific treatment functions. These products are designed to provide targeted drug delivery, enhance drug efficacy, improve patient compliance, or enable novel treatment modalities that may not be achievable with conventional drug formulations or medical devices alone. These products encompass various healthcare interventions, including drug-eluting stents, insulin pumps, contraceptive implants, and inhalation devices. These innovative products offer potential advantages in precision medicine, personalized therapy, and patient convenience, driving advancements in medical treatment and improving patient outcomes across various therapeutic areas.

MARKET DYNAMICS

The rising demand for tailored medicine and targeted therapies drives the development of innovative drug-device combination products that offer precise drug delivery mechanisms and improved patient compliance. As healthcare providers and patients seek more effective and convenient treatment options, there's a rising interest in combination products that combine pharmaceuticals' therapeutic benefits with medical devices' precision and reliability. Additionally, drug formulation technologies and device design advancements enable the development of novel combination products for numerous medical conditions, ranging from chronic diseases to acute conditions. Moreover, regulatory initiatives and guidelines governing combination products, such as the FDA's Combination Product Policy and the EU's Medical Device Regulation (MDR), provide a framework for manufacturers to navigate the complex regulatory landscape and bring innovative products to market.

Furthermore, strategic collaborations between pharmaceutical companies, medical device manufacturers, and research institutions drive innovation and drug-device combination products market expansion, fostering the development of new drug-device combination products across therapeutic areas. Increasing healthcare expenditure and reimbursement support for combination products incentivize investment in research and development, further driving drug-device combination products market growth. However, regulatory hurdles and complexities associated with combination product development and reimbursement challenges may challenge the drug device combination products market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Drug Device Combination Products. The growth and trends of Drug Device Combination Products industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Drug Device Combination Products market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Drug-Eluting Stents (Coronary Drug-Elating Stents, Peripheral Drug-Eluting Stents)
Infusion Pumps (Implantable Infusion Pumps, Insulin Infusion Pumps, Patient-Controlled Analgesia Pumps, Ambulatory Infusion Pumps, Volumetric Infusion Pumps, Disposable Infusion Pumps)
Photodynamic Therapy
Wound Care Combination Product
Prefilled Syringes (Single-Chamber Prefilled Syringes, Dual-Chamber Prefilled Syringes, Customized Prefilled Syringes)
Drug-Eluting Balloons (Coronary Drug-Eluting Balloons, Peripheral Drug-Eluting Balloons)
Nebulizers
Inhalers (Drug Powdered Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs))
Transdermal Delivery Systems (Active Transdermal Systems, Passive Transdermal Systems)
Orthopedic Combination Products (Bone Graft Implants, Antibiotic Loaded Bone Cement)
Antimicrobial Catheters (Urological Catheters, Cardiovascular Catheters, Other Catheters, Other Products)

By Application

Cardiovascular Disorders
Diabetes
Respiratory Problems
Cancer Treatment
Antimicrobial Application
Other

By End-use

Hospitals And Clinics
Ambulatory Surgical Centers
Home Care Settings
Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Drug Device Combination Products market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Drug Device Combination Products market include Abbott Laboratories, AbbVie Inc., Alcon Inc., Bausch Health Companies Inc, Baxter International Inc., Bayer AG, Becton, Dickinson And Company, Boston Scientific Corporation, GlaxoSmithKline Plc, Johnson & Johnson, Kaleo Inc., Medtronic Plc, Novartis AG, Sinomed, Smith & Nephew Plc, Teleflex Incorporated, Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114874

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. DRUG DEVICE COMBINATION PRODUCTS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data Analysis By Product
5.3. Drug-Eluting Stents (Coronary Drug-Elating Stents, Peripheral Drug-Eluting Stents) Historic and Forecast Sales By Regions
5.4. Infusion Pumps (Implantable Infusion Pumps, Insulin Infusion Pumps, Patient-Controlled Analgesia Pumps, Ambulatory Infusion Pumps, Volumetric Infusion Pumps, Disposable Infusion Pumps) Historic and Forecast Sales By Regions
5.5. Photodynamic Therapy Historic and Forecast Sales By Regions
5.6. Wound Care Combination Product Historic and Forecast Sales By Regions
5.7. Prefilled Syringes (Single-Chamber Prefilled Syringes, Dual-Chamber Prefilled Syringes, Customized Prefilled Syringes) Historic and Forecast Sales By Regions
5.8. Drug-Eluting Balloons (Coronary Drug-Eluting Balloons, Peripheral Drug-Eluting Balloons) Historic and Forecast Sales By Regions
5.9. Nebulizers Historic and Forecast Sales By Regions
5.10. Inhalers (Drug Powdered Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs)) Historic and Forecast Sales By Regions
5.11. Transdermal Delivery Systems (Active Transdermal Systems, Passive Transdermal Systems) Historic and Forecast Sales By Regions
5.12. Orthopedic Combination Products (Bone Graft Implants, Antibiotic Loaded Bone Cement) Historic and Forecast Sales By Regions
5.13. Antimicrobial Catheters (Urological Catheters, Cardiovascular Catheters, Other Catheters, Other Products) Historic and Forecast Sales By Regions

6. GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Cardiovascular Disorders Historic and Forecast Sales By Regions
6.4. Diabetes Historic and Forecast Sales By Regions
6.5. Respiratory Problems Historic and Forecast Sales By Regions
6.6. Cancer Treatment Historic and Forecast Sales By Regions
6.7. Antimicrobial Application Historic and Forecast Sales By Regions
6.8. Other Historic and Forecast Sales By Regions

7. GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS BY END-USE

7.1. Overview By End-use
7.2. Historical and Forecast Data Analysis By End-use
7.3. Hospitals And Clinics Historic and Forecast Sales By Regions
7.4. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
7.5. Home Care Settings Historic and Forecast Sales By Regions
7.6. Other Historic and Forecast Sales By Regions

8. GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE DRUG DEVICE COMBINATION PRODUCTS COMPANIES

9.1. Drug Device Combination Products Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF DRUG DEVICE COMBINATION PRODUCTS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abbott Laboratories
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. AbbVie Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Alcon Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Bausch Health Companies Inc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Baxter International Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Bayer AG
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Becton, Dickinson And Company
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Teva Pharmaceutical Industries Ltd
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Boston Scientific Corporation
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. GlaxoSmithKline Plc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Johnson & Johnson
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Kaleo Inc.
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Medtronic Plc
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Novartis AG
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Sinomed
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Smith & Nephew Plc
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments
10.19. Teleflex Incorporated
- 10.19.1 Company Overview
- 10.19.2 Company Revenue
- 10.19.3 Products
- 10.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies